Acquisition of clofazimine resistance following bedaquiline treatment for multidrug-resistant tuberculosis

This publication has 18 references indexed in Scilit:

• The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis
  The Lancet Respiratory Medicine, 2017
• Elucidating the role of clofazimine for the treatment of tuberculosis
  The International Journal of Tuberculosis and Lung Disease, 2016
• Mutations in pepQ Confer Low-Level Resistance to Bedaquiline and Clofazimine in Mycobacterium tuberculosis
  Antimicrobial Agents and Chemotherapy, 2016
• Mechanisms of drug resistance in Mycobacterium tuberculosis: update 2015
  The International Journal of Tuberculosis and Lung Disease, 2015
• Identification of novel mutations associated with clofazimine resistance inMycobacterium tuberculosis: Table 1.
  Journal of Antimicrobial Chemotherapy, 2015
• Cross-Resistance between Clofazimine and Bedaquiline through Upregulation of MmpL5 in Mycobacterium tuberculosis
  Antimicrobial Agents and Chemotherapy, 2014
• In vitro and in vivo activity of clofazimine against Mycobacterium tuberculosis persisters
  The International Journal of Tuberculosis and Lung Disease, 2012
• Clofazimine: current status and future prospects
  Journal of Antimicrobial Chemotherapy, 2011
• The mitochondrial theory of aging and its relationship to reactive oxygen species damage and somatic mtDNA mutations
  Proceedings of the National Academy of Sciences, 2005
• Classification of drug-resistant tuberculosis in an epidemic area
  The Lancet, 2000